logo
科言猫学术研究的AI总结
language
手机端手机端
  • Phone Feature微信小程序
简体中文简体中文
notice消息通知
博客博客
arrow
S

Shinsuke Shiotsu

Japanese Red Cross Kyoto Daiichi Hospital
H指数:17
被引数:1,398

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Gut microbiome-driven modulation of the tumor immune microenvironment optimizes dual checkpoint blockade in advanced non-small-cell lung cancer

肠道微生物组驱动的肿瘤免疫微环境调控优化了晚期非小细胞肺癌的双检查点阻断

ESMO Open
IF8.3
2026-02-160
OAAI
Y. Katayama; A. Fukuda; R. Inoue; H. Kawachi; R. Sawada; T. Harada; A. Yoshimura; A. Okada; S. Shiotsu; Y. Chihara; Y. Takemura; T. Yamada; N. Nishioka; M. Iwasaku; S. Tokuda; T. Takagi; S. Kumagai; S. Koyama; K. Takayama; T. Yamada
Selecting optimal immunotherapy based on inflammation in stage IV PD-L1 ≥50% gene mutation-negative non-small cell lung cancer: pembrolizumab monotherapy versus combination chemoimmunotherapy

基于炎症选择最优免疫疗法：用于PD-L1 ≥50%基因突变阴性IV期非小细胞肺癌：帕博利珠单抗单药治疗与联合化疗免疫疗法

TRANSLATIONAL LUNG CANCER RESEARCH
IF3.5
2025-11-300
PRE
Kunimatsu, Yusuke; Nishioka, Naoya; Yamada, Tadaaki; Kawachi, Hayato; Tamiya, Motohiro; Negi, Yoshiki; Goto, Yasuhiro; Nakao, Akira; Shiotsu, Shinsuke; Tanimura, Keiko; Takeda, Takayuki; Okada, Asuka; Harada, Taishi; Date, Koji; Chihara, Yusuke; Hasegawa, Isao; Tamiya, Nobuyo; Ishida, Masaki; Kijima, Takashi; Takayama, Koichi
Clinical impact of cancer cachexia on the outcome of patients with non-small cell lung cancer with PD-L1 tumor proportion scores of ≥50% receiving pembrolizumab monotherapy versus immune checkpoint inhibitor with chemotherapy
ONCOIMMUNOLOGY
IF6.3
2024-12-160
OAAI
Kawachi, Hayato; Yamada, Tadaaki; Tamiya, Motohiro; Negi, Yoshiki; Kijima, Takashi; Goto, Yasuhiro; Nakao, Akira; Shiotsu, Shinsuke; Tanimura, Keiko; Takeda, Takayuki; Okada, Asuka; Harada, Taishi; Date, Koji; Chihara, Yusuke; Hasegawa, Isao; Tamiya, Nobuyo; Katayama, Yuki; Nishioka, Naoya; Morimoto, Kenji; Iwasaku, Masahiro; Tokuda, Shinsaku; Shimose, Takayuki; Takayama, Koichi
The impact of antibiotic use on ICI plus chemotherapy versus chemotherapy in NSCLC patients with PD-L1 expression of 1% to 49%

PD-L1表达为1%至49%的NSCLC患者中，抗生素使用对ICI联合化疗与化疗的影响

ANNALS OF ONCOLOGY
IF65.4
2024-12-010
PRE
Toyota, Y.; Hata, T.; Yamada, T.; Goto, Y.; Kijima, T.; Watanabe, S.; Furuya, N.; Oba, T.; Ikoma, T.; Nakao, A.; Tanimura, K.; Taniguchi, H.; Yoshimura, A.; Fukui, T.; Murata, D.; Kaira, K.; Shiotsu, S.; Hibino, M.; Okada, A.; Takayama, K.
Chemoimmunotherapy versus pembrolizumab as a fi rst-line treatment for patients with advanced non-small cell lung cancer and high PD-L1 expression: Focus on the role of performance status

化疗免疫疗法与帕博利珠单抗作为PD-L1高表达晚期非小细胞肺癌患者一线治疗的选择：聚焦于体力状况的作用

ANNALS OF ONCOLOGY
IF65.4
2024-12-010
PRE
Yamada, T.; Morimoto, K.; Kawachi, H.; Tamiya, M.; Negi, Y.; Goto, Y.; Nakao, A.; Shiotsu, S.; Tanimura, K.; Okada, A.; Date, K.; Harada, T.; Chihara, Y.; Hasegawa, I.; Tamiya, N.; Kijima, T.; Takayama, K.
Impact of TTF-1 Expression on the Prognostic Prediction of Patients with Non-Small Cell Lung Cancer with PD-L1 Expression Levels of 1%to 49%, Treated with Chemotherapy vs. Chemoimmunotherapy: A Multicenter, Retrospective Study

TTF-1表达对PD-L1表达水平为1%至49%的非小细胞肺癌患者预后预测的影响：化疗与化疗免疫治疗的多中心回顾性研究

CANCER RESEARCH AND TREATMENT
IF3.8
2024-10-250
OA
Nishioka, Naoya; Hata, Tae; Yamada, Tadaaki; Goto, Yasuhiro; Amano, Akihiko; Negi, Yoshiki; Watanabe, Satoshi; Furuya, Naoki; Oba, Tomohiro; Ikoma, Tatsuki; Nakao, Akira; Tanimura, Keiko; Taniguchi, Hirokazu; Yoshimura, Akihiro; Fukui, Tomoya; Murata, Daiki; Kaira, Kyoichi; Shiotsu, Shinsuke; Hibino, Makoto; Okada, Asuka; Chihara, Yusuke; Kawachi, Hayato; Kijima, Takashi; Takayama, Koichi
Depth of response and treatment outcomes of immune checkpoint inhibitor-based therapy in patients with advanced non-small cell lung cancer and high PD-L1 expression: An exploratory analysis of retrospective multicenter cohort
INVESTIGATIONAL NEW DRUGS
IF2.7
2024-08-210
PRE
Tachibana, Yusuke; Morimoto, Kenji; Yamada, Tadaaki; Kawachi, Hayato; Tamiya, Motohiro; Negi, Yoshiki; Goto, Yasuhiro; Nakao, Akira; Shiotsu, Shinsuke; Tanimura, Keiko; Takeda, Takayuki; Okada, Asuka; Harada, Taishi; Date, Koji; Chihara, Yusuke; Hasegawa, Isao; Tamiya, Nobuyo; Katayama, Yuki; Nishioka, Naoya; Iwasaku, Masahiro; Tokuda, Shinsaku; Kijima, Takashi; Takayama, Koichi
CYFRA 21-1 predicts efficacy of combined chemoimmunotherapy in patients with advanced non-small cell lung cancer: a prospective observational study
TRANSLATIONAL LUNG CANCER RESEARCH
IF3.5
2024-08-010
OAAI
Kataoka, Nobutaka; Katayama, Yuki; Yamada, Tadaaki; Morimoto, Kenji; Takeda, Takayuki; Okada, Asuka; Shiotsu, Shinsuke; Chihara, Yusuke; Yamada, Takahiro; Hiranuma, Osamu; Ota, Takahiro; Harada, Taishi; Hasegawa, Isao; Nishioka, Naoya; Iwasaku, Masahiro; Tokuda, Shinsaku; Takayama, Koichi
Unraveling the influence of TTF-1 expression on immunotherapy outcomes in PD-L1-high non-squamous NSCLC: a retrospective multicenter study
FRONTIERS IN IMMUNOLOGY
IF5.9
2024-07-150
OAAI
Nishioka, Naoya; Kawachi, Hayato; Yamada, Tadaaki; Tamiya, Motohiro; Negi, Yoshiki; Goto, Yasuhiro; Nakao, Akira; Shiotsu, Shinsuke; Tanimura, Keiko; Takeda, Takayuki; Okada, Asuka; Harada, Taishi; Date, Koji; Chihara, Yusuke; Hasegawa, Isao; Tamiya, Nobuyo; Masui, Taiki; Sai, Natsuki; Ishida, Masaki; Katayama, Yuki; Morimoto, Kenji; Iwasaku, Masahiro; Tokuda, Shinsaku; Kijima, Takashi; Takayama, Koichi
AXL signal mediates adaptive resistance to KRAS G12C inhibitors in KRAS G12C-mutant tumor cells

AXL信号介导KRAS G12C-mutant肿瘤细胞对KRAS G12C抑制剂的适应性耐药

CANCER LETTERS
IF10.1
2024-04-010
OAAI
Morimoto, Kenji; Yamada, Tadaaki; Hirai, Soichi; Katayama, Yuki; Fukui, Sarina; Sawada, Ryo; Tachibana, Yusuke; Matsui, Yohei; Nakamura, Ryota; Ishida, Masaki; Kawachi, Hayato; Kunimasa, Kei; Sasaki, Takaaki; Nishida, Makoto; Furuya, Naoki; Watanabe, Satoshi; Shiotsu, Shinsuke; Nishioka, Naoya; Horinaka, Mano; Sakai, Toshiyuki; Uehara, Hisanori; Yano, Seiji; Son, Bo-Kyung; Tokuda, Shinsaku; Takayama, Koichi
Association between clinical characteristics and treatment outcome of immune checkpoint inhibitor with or without chemotherapy in elderly non-small cell lung cancer patients with high PD-L1 expression
CANCER RESEARCH
IF16.6
2024-03-220
PRE
Kawachi, Hayato; Takei, Shota; Yamada, Tadaaki; Tamiya, Motohiro; Negi, Yoshiki; Goto, Yasuhiro; Nakao, Akira; Shiotsu, Shinsuke; Takeda, Takayuki; Okada, Asuka; Harada, Taishi; Date, Koji; Chihara, Yusuke; Hasegawa, Isao; Tamiya, Nobuyo; Kijima, Takashi; Takayama, Koichi
Comparing Three Different Anti-Programmed Death-Ligand 1 Antibodies in Immunohistochemical Evaluation of Combined Chemoimmunotherapy Response in Patients With NSCLC: A Prospective Study
JTO CLINICAL AND RESEARCH REPORTS
IF3.5
2024-03-010
OA
Katayama, Yuki; Yamada, Tadaaki; Morimoto, Kenji; Fujii, Hiroyuki; Morita, Satomi; Tanimura, Keiko; Takeda, Takayuki; Okada, Asuka; Shiotsu, Shinsuke; Chihara, Yusuke; Hiranuma, Osamu; Yamada, Takahiro; Ota, Takahiro; Harada, Taishi; Hasegawa, Isao; Iwasaku, Masahiro; Tokuda, Shinsaku; Tanaka, Noriyuki; Miyagawa-Hayashino, Aya; Takayama, Koichi
Prognostic impact of clinical factors for immune checkpoint inhibitor with or without chemotherapy in older patients with non-small cell lung cancer and PD-L1 TPS ≥ 50%

免疫检查点抑制剂联合化疗对TPS ≥ 50% 的老年非小细胞肺癌PD-L1预后的影响

FRONTIERS IN IMMUNOLOGY
IF5.9
2024-02-232
OAAI
Takei, Shota; Kawachi, Hayato; Yamada, Tadaaki; Tamiya, Motohiro; Negi, Yoshiki; Goto, Yasuhiro; Nakao, Akira; Shiotsu, Shinsuke; Tanimura, Keiko; Takeda, Takayuki; Okada, Asuka; Harada, Taishi; Date, Koji; Chihara, Yusuke; Hasegawa, Isao; Tamiya, Nobuyo; Katayama, Yuki; Nishioka, Naoya; Morimoto, Kenji; Iwasaku, Masahiro; Tokuda, Shinsaku; Kijima, Takashi; Takayama, Koichi
Impact of the response to platinum-based chemotherapy on the second-line immune checkpoint inhibitor monotherapy in non-small cell lung cancer with PD-L1 expression ≤49%: a multicenter retrospective study
FRONTIERS IN ONCOLOGY
IF3.3
2024-01-260
OAAI
Yoshimura, Akihiro; Takeda, Takayuki; Kataoka, Nobutaka; Tanimura, Keiko; Fukui, Mototaka; Chihara, Yusuke; Takei, Shota; Kawachi, Hayato; Nakanishi, Kentaro; Yamanaka, Yuta; Tamiya, Nobuyo; Honda, Ryoichi; Okura, Naoko; Yamada, Takahiro; Uryu, Kiyoaki; Murai, Junji; Shiotsu, Shinsuke; Yoshioka, Hiroshige; Yamada, Tadaaki; Kurata, Takayasu; Takayama, Koichi
Chemoimmunotherapy Versus Pembrolizumab as a First-Line Treatment for Patients with Advanced Non-small Cell Lung Cancer and High PD-L1 Expression: Focus on the Role of Performance Status
TARGETED ONCOLOGY
IF4
2023-10-302
PRE
Morimoto, Kenji; Yamada, Tadaaki; Kawachi, Hayato; Tamiya, Motohiro; Negi, Yoshiki; Goto, Yasuhiro; Nakao, Akira; Shiotsu, Shinsuke; Tanimura, Keiko; Takeda, Takayuki; Okada, Asuka; Harada, Taishi; Date, Koji; Chihara, Yusuke; Hasegawa, Isao; Tamiya, Nobuyo; Nishioka, Naoya; Katayama, Yuki; Iwasaku, Masahiro; Tokuda, Shinsaku; Kijima, Takashi; Takayama, Koichi
Clinical impact of proton pump inhibitor on the therapeutic outcome of non-small cell lung cancer patients with PD-L1 TPS I50% receiving pembrolizumab monotherapy versus immune checkpoint inhibitor plus chemotherapy: A retrospective multicenter cohort study
ANNALS OF ONCOLOGY
IF65.4
2023-10-010
OA
Kawachi, H.; Yamada, T.; Tamiya, M.; Negi, Y.; Goto, Y.; Nakao, A.; Shiotsu, S.; Tanimura, K.; Takeda, T.; Okada, A.; Harada, T.; Date, K.; Chihara, Y.; Hasegawa, I.; Tamiya, N.; Iwasaku, M.; Tokuda, S.; Kijima, T.; Takayama, K.

研究方向

暂未获取到该数据
T
Tadaaki Yamada
H 指数:41论文数:563被引数:6,302
K
Koichi Takayama
H 指数:75论文数:954被引数:1.9万
Y
Yusuke Chihara
H 指数:23论文数:157被引数:3,155
T
Takayuki Takeda
H 指数:22论文数:196被引数:2,738
M
Masahiro Iwasaku
H 指数:24论文数:135被引数:1,900
K
Kenji Morimoto
H 指数:27论文数:222被引数:4,300
T
Taishi Harada
H 指数:32论文数:221被引数:3,858
K
Keiko Tanimura
H 指数:13论文数:107被引数:1,066
Y
Yuki Katayama
H 指数:17论文数:88被引数:1,123
S
Shinsaku Tokuda
H 指数:19论文数:120被引数:1,582